June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
UK outcomes of providing aflibercept, according to the VIEW protocol, for treatment naïve neovascular age-related macular degeneration.
Author Affiliations & Notes
  • James S Talks
    Ophthalmology, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
  • Footnotes
    Commercial Relationships James Talks, Bayer (R), Novartis (R)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 4602. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      James S Talks, ; UK outcomes of providing aflibercept, according to the VIEW protocol, for treatment naïve neovascular age-related macular degeneration.. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):4602.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To collect and assess data on visual acuity outcomes, from multiple centres in the UK, using aflibercept for neovascular age-related macular degeneration, following the VIEW protocol. Aflibercept has the potential advantage of allowing 2 monthly treatment schedules, which has significant advanatages for patients and carers, as well as for the capacity of providers, compared to other anti-VEGF treatments. We wanted to see if the aflibercept trial results can be replicated in practice from a large sample.

Methods: Visual acuity data has been collected on patients treated at 6 centres with aflibercept, from Medisoft, an electronic patient record. Aflibercept was started in the UK in most centres by August 2013. Data cut presented is from end of November 2014. Data collection is on-going and 7 more centres are due to contribute shortly.

Results: At base line 1795 patients had a mean visual acuity of 54.8 ETRDS letters. At one year 250 patients had a mean visual acuity of 60.8, + 6 letter mean gain. 19.2% had ≥ 70 letters (approx. 6/12) at base line and 35% at one year. 49.2% gained >5 letters with 19% > 15 letters; 23% lost > 5 letters with 6.2% > 15 letters. Median number of injections actually given was 7.

Conclusions: The visual acuity outcomes compare reasonably to trial outcomes, with a 6 letter mean gain compared to 8.5 in View. This is encouraging compared to many previously published results showing results in clinical practice with other anti-VEGF treatments.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×